CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy

Woong Sub Koom, Jinsil Seong, Yong Bae Kim, Hae Ok Pyun, Si Young Song

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: To investigate the significance of carbohydrate antigen 19-9 (CA 19-9) levels for predicting response and survival in pancreatic cancer (PC) treated with concurrent chemoradiotherapy. Methods and Materials: We retrospectively reviewed data from 69 patients with PC between 1999 and 2005. All patients had elevated CA 19-9 levels before treatment. CA 19-9 levels (pre- and posttreatment CA 19-9) and their decline were analyzed for radiologic response and overall survival. Results: Seventeen patients (25%) had a 50% or greater reduction in tumor size within 3 months of chemoradiotherapy (1 complete response, 16 partial responses). CA 19-9 decline was significantly correlated with radiologic response (p = 0.03). The median survival time (MST) was 12 months (range, 4-48 months), and 1-year survival rate was 44%. Pretreatment CA 19-9 > 1,200 U/mL (MST, 13 vs. 8 months; p = 0.002), posttreatment CA 19-9 >100 U/mL (MST, 17 vs. 10 months; p = 0.0003), and CA 19-9 decline ≤40% (MST, 13 vs. 10 months; p = 0.005) were the strongest and most unfavorable prognostic factors. In addition, patients with multiple unfavorable CA 19-9 levels had significantly worse outcomes than those without. Conclusions: CA 19-9 decline shows a correlation with radiologic response. The combination of pretreatment CA 19-9 >1,200 U/mL, posttreatment CA 19-9 >100 U/mL, and CA 19-9 decline ≤40% may possibly serve as a surrogate marker for poor survival in advanced PC receiving chemoradiotherapy.

Original languageEnglish
Pages (from-to)1148-1154
Number of pages7
JournalInternational Journal of Radiation Oncology Biology Physics
Volume73
Issue number4
DOIs
Publication statusPublished - 2009 Mar 15

Fingerprint

carbohydrates
Chemoradiotherapy
antigens
Pancreatic Neoplasms
cancer
Carbohydrates
Antigens
Survival
predictions
pretreatment
markers
tumors
Survival Rate
Biomarkers

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

@article{7c922291f1d3435e979e64507b3399d4,
title = "CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy",
abstract = "Purpose: To investigate the significance of carbohydrate antigen 19-9 (CA 19-9) levels for predicting response and survival in pancreatic cancer (PC) treated with concurrent chemoradiotherapy. Methods and Materials: We retrospectively reviewed data from 69 patients with PC between 1999 and 2005. All patients had elevated CA 19-9 levels before treatment. CA 19-9 levels (pre- and posttreatment CA 19-9) and their decline were analyzed for radiologic response and overall survival. Results: Seventeen patients (25{\%}) had a 50{\%} or greater reduction in tumor size within 3 months of chemoradiotherapy (1 complete response, 16 partial responses). CA 19-9 decline was significantly correlated with radiologic response (p = 0.03). The median survival time (MST) was 12 months (range, 4-48 months), and 1-year survival rate was 44{\%}. Pretreatment CA 19-9 > 1,200 U/mL (MST, 13 vs. 8 months; p = 0.002), posttreatment CA 19-9 >100 U/mL (MST, 17 vs. 10 months; p = 0.0003), and CA 19-9 decline ≤40{\%} (MST, 13 vs. 10 months; p = 0.005) were the strongest and most unfavorable prognostic factors. In addition, patients with multiple unfavorable CA 19-9 levels had significantly worse outcomes than those without. Conclusions: CA 19-9 decline shows a correlation with radiologic response. The combination of pretreatment CA 19-9 >1,200 U/mL, posttreatment CA 19-9 >100 U/mL, and CA 19-9 decline ≤40{\%} may possibly serve as a surrogate marker for poor survival in advanced PC receiving chemoradiotherapy.",
author = "Koom, {Woong Sub} and Jinsil Seong and Kim, {Yong Bae} and Pyun, {Hae Ok} and Song, {Si Young}",
year = "2009",
month = "3",
day = "15",
doi = "10.1016/j.ijrobp.2008.06.1483",
language = "English",
volume = "73",
pages = "1148--1154",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy. / Koom, Woong Sub; Seong, Jinsil; Kim, Yong Bae; Pyun, Hae Ok; Song, Si Young.

In: International Journal of Radiation Oncology Biology Physics, Vol. 73, No. 4, 15.03.2009, p. 1148-1154.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CA 19-9 as a Predictor for Response and Survival in Advanced Pancreatic Cancer Patients Treated With Chemoradiotherapy

AU - Koom, Woong Sub

AU - Seong, Jinsil

AU - Kim, Yong Bae

AU - Pyun, Hae Ok

AU - Song, Si Young

PY - 2009/3/15

Y1 - 2009/3/15

N2 - Purpose: To investigate the significance of carbohydrate antigen 19-9 (CA 19-9) levels for predicting response and survival in pancreatic cancer (PC) treated with concurrent chemoradiotherapy. Methods and Materials: We retrospectively reviewed data from 69 patients with PC between 1999 and 2005. All patients had elevated CA 19-9 levels before treatment. CA 19-9 levels (pre- and posttreatment CA 19-9) and their decline were analyzed for radiologic response and overall survival. Results: Seventeen patients (25%) had a 50% or greater reduction in tumor size within 3 months of chemoradiotherapy (1 complete response, 16 partial responses). CA 19-9 decline was significantly correlated with radiologic response (p = 0.03). The median survival time (MST) was 12 months (range, 4-48 months), and 1-year survival rate was 44%. Pretreatment CA 19-9 > 1,200 U/mL (MST, 13 vs. 8 months; p = 0.002), posttreatment CA 19-9 >100 U/mL (MST, 17 vs. 10 months; p = 0.0003), and CA 19-9 decline ≤40% (MST, 13 vs. 10 months; p = 0.005) were the strongest and most unfavorable prognostic factors. In addition, patients with multiple unfavorable CA 19-9 levels had significantly worse outcomes than those without. Conclusions: CA 19-9 decline shows a correlation with radiologic response. The combination of pretreatment CA 19-9 >1,200 U/mL, posttreatment CA 19-9 >100 U/mL, and CA 19-9 decline ≤40% may possibly serve as a surrogate marker for poor survival in advanced PC receiving chemoradiotherapy.

AB - Purpose: To investigate the significance of carbohydrate antigen 19-9 (CA 19-9) levels for predicting response and survival in pancreatic cancer (PC) treated with concurrent chemoradiotherapy. Methods and Materials: We retrospectively reviewed data from 69 patients with PC between 1999 and 2005. All patients had elevated CA 19-9 levels before treatment. CA 19-9 levels (pre- and posttreatment CA 19-9) and their decline were analyzed for radiologic response and overall survival. Results: Seventeen patients (25%) had a 50% or greater reduction in tumor size within 3 months of chemoradiotherapy (1 complete response, 16 partial responses). CA 19-9 decline was significantly correlated with radiologic response (p = 0.03). The median survival time (MST) was 12 months (range, 4-48 months), and 1-year survival rate was 44%. Pretreatment CA 19-9 > 1,200 U/mL (MST, 13 vs. 8 months; p = 0.002), posttreatment CA 19-9 >100 U/mL (MST, 17 vs. 10 months; p = 0.0003), and CA 19-9 decline ≤40% (MST, 13 vs. 10 months; p = 0.005) were the strongest and most unfavorable prognostic factors. In addition, patients with multiple unfavorable CA 19-9 levels had significantly worse outcomes than those without. Conclusions: CA 19-9 decline shows a correlation with radiologic response. The combination of pretreatment CA 19-9 >1,200 U/mL, posttreatment CA 19-9 >100 U/mL, and CA 19-9 decline ≤40% may possibly serve as a surrogate marker for poor survival in advanced PC receiving chemoradiotherapy.

UR - http://www.scopus.com/inward/record.url?scp=61349202170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61349202170&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2008.06.1483

DO - 10.1016/j.ijrobp.2008.06.1483

M3 - Article

C2 - 18760544

AN - SCOPUS:61349202170

VL - 73

SP - 1148

EP - 1154

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -